Virax Biolabs Group Limited (NASDAQ:VRAX – Get Free Report) saw a large decrease in short interest in the month of July. As of July 15th, there was short interest totalling 41,300 shares, a decrease of 36.6% from the June 30th total of 65,100 shares. Approximately 2.4% of the shares of the company are sold short. Based on an average daily volume of 1,420,000 shares, the days-to-cover ratio is presently 0.0 days.
Institutional Investors Weigh In On Virax Biolabs Group
An institutional investor recently bought a new position in Virax Biolabs Group stock. Armistice Capital LLC purchased a new stake in Virax Biolabs Group Limited (NASDAQ:VRAX – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 121,999 shares of the company’s stock, valued at approximately $178,000. Armistice Capital LLC owned 7.87% of Virax Biolabs Group as of its most recent SEC filing. 8.61% of the stock is currently owned by institutional investors and hedge funds.
Virax Biolabs Group Stock Up 17.1 %
Shares of VRAX stock traded up $0.20 on Friday, reaching $1.37. The stock had a trading volume of 237,852 shares, compared to its average volume of 108,854. The firm’s 50-day moving average is $1.26 and its two-hundred day moving average is $0.98. Virax Biolabs Group has a 12 month low of $0.60 and a 12 month high of $4.30.
Virax Biolabs Group Company Profile
Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.
Recommended Stories
- Five stocks we like better than Virax Biolabs Group
- Conference Calls and Individual Investors
- Why Call Options Volume for These 2 Stocks Spiked Together
- Retail Stocks Investing, Explained
- MarketBeat Week in Review – 7/22 – 7/26
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
Receive News & Ratings for Virax Biolabs Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virax Biolabs Group and related companies with MarketBeat.com's FREE daily email newsletter.